Table 1.
Select baseline characteristics of epithelial ovarian cancer cases among 169,391 women in NIH-AARP Diet and Health Study, 1995-2006
| Epithelial Cases (N=849) |
Histological Subtypes |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Study Subjects | Non-Cases (N=168,542) |
Serous (N=451) |
Endometrioid (N=78) |
Mucinous (N=38) |
Clear Cell (N=27) |
Other (N=255) |
||||||||||
| Person-Years | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | |
| Race/ethnicity | ||||||||||||||||
| White | 1,488,349 | 90% | 151,329 | 90% | 792 | 93% | 425 | 94% | 71 | 91% | 36 | 95% | 26 | 96% | 234 | 92% |
| Non-White | 169,618 | 10% | 17,213 | 10% | 57 | 7% | 26 | 6% | 7 | 9% | 2 | 5% | 1 | 4% | 21 | 8% |
| Age (years) | ||||||||||||||||
| Mean (standard deviation) | 61.8 (5.4) | 62.8 (5.3) | 62.6 (5.4) | 61.0 (6.2) | 63.5 (5.5) | 59.7 (6.2) | 63.9 (4.8) | |||||||||
| < 55 | 250,797 | 15% | 24,960 | 15% | 90 | 11% | 52 | 12% | 8 | 10% | 4 | 11% | 9 | 33% | 17 | 7% |
| 55-59 | 388,246 | 23% | 39,027 | 23% | 178 | 21% | 92 | 20% | 32 | 41% | 6 | 16% | 6 | 22% | 42 | 16% |
| 60-64 | 460,607 | 28% | 46,791 | 28% | 214 | 25% | 121 | 27% | 15 | 19% | 7 | 18% | 5 | 19% | 66 | 26% |
| 65-69 | 503,078 | 30% | 51,945 | 31% | 326 | 38% | 164 | 36% | 21 | 27% | 18 | 47% | 5 | 19% | 118 | 46% |
| ≥ 70 | 55,239 | 3% | 5,819 | 3% | 41 | 5% | 22 | 5% | 2 | 3% | 3 | 8% | 2 | 7% | 12 | 5% |
| Education | ||||||||||||||||
| ≤ High school | 508,307 | 32% | 51,854 | 32% | 245 | 30% | 116 | 27% | 27 | 35% | 14 | 39% | 10 | 37% | 78 | 32% |
| > High school | 1,099,530 | 68% | 111,531 | 68% | 570 | 70% | 313 | 73% | 50 | 65% | 22 | 61% | 17 | 63% | 168 | 68% |
| Age at menopause (years) | ||||||||||||||||
| Premenopausal | 76,000 | 6% | 7,517 | 6% | 24 | 4% | 17 | 5% | 1 | 2% | 0 | 0% | 3 | 14% | 3 | 2% |
| < 45 | 133,288 | 11% | 13,847 | 11% | 56 | 9% | 34 | 11% | 2 | 4% | 2 | 6% | 1 | 5% | 17 | 9% |
| 45-49 | 314,026 | 26% | 32,073 | 26% | 158 | 26% | 81 | 26% | 13 | 25% | 12 | 38% | 8 | 38% | 44 | 24% |
| 50-54 | 549,816 | 46% | 55,539 | 46% | 293 | 49% | 144 | 46% | 29 | 56% | 15 | 47% | 9 | 43% | 96 | 53% |
| ≥ 55 | 123,882 | 10% | 12,516 | 10% | 67 | 11% | 35 | 11% | 7 | 13% | 3 | 9% | 0 | 0% | 22 | 12% |
| Stage at diagnosisα | ||||||||||||||||
| In situ/Localized | 49 | 10% | 14 | 6% | 18 | 41% | 11 | 42% | 1 | 10% | 5 | 4% | ||||
| Regional/distant metastases | 422 | 90% | 239 | 94% | 26 | 59% | 15 | 58% | 9 | 90% | 133 | 96% | ||||
| Grade at diagnosis | ||||||||||||||||
| Grade I | 44 | 7% | 23 | 6% | 10 | 14% | 7 | 25% | 1 | 5% | 3 | 2% | ||||
| Grade II | 134 | 22% | 79 | 21% | 25 | 36% | 11 | 39% | 2 | 11% | 17 | 14% | ||||
| Grade III-IV | 435 | 71% | 271 | 73% | 34 | 49% | 10 | 36% | 16 | 84% | 104 | 84% | ||||
Numbers may not add up to total because of missing values. Missing values were excluded from percentage calculations.
α
SEER Summary Staging Manual 2000: in situ/localized, regional/distant metases